Morgan Stanley raises Alpine Immune Sciences' price target to $47 on March 14.

Morgan Stanley raised its price target for Alpine Immune Sciences (ALPN) from $30 to $47 on March 14. The brokerage maintains an "overweight" rating on the biotech company's stock. Several other analysts have also given positive ratings, including Oppenheimer's "outperform" rating and HC Wainwright's "buy" rating. Alpine Immune Sciences reported better-than-expected Q4 earnings, with GAAP earnings of $0.15 per share and revenues of $30.85 million.

March 19, 2024
5 Articles